ESTEVE Acquires Caprelsa® to Boost Cancer Treatment Portfolio
Deal News | Jun 30, 2025 | PR Newswire Cision ESTEVE
ESTEVE, a global pharmaceutical company headquartered in Barcelona, has announced its acquisition of the rights to Caprelsa® (vandetanib) for treating medullary thyroid cancer in a deal with Sanofi. Caprelsa® is a tyrosine kinase inhibitor used for adult and pediatric patients above 5 years to treat aggressive and symptomatic medullary thyroid cancer. This acquisition covers over 50 countries, marking a significant step in ESTEVE's international growth strategy focusing on specialized treatments for unmet medical needs. José María Giménez-Arnau, ESTEVE’s Chief Scientific & Medical Officer, expressed commitment to advancing cancer treatments, while Jacob Tolstrup, Chief Commercial Officer, affirmed the expansion of ESTEVE’s portfolio with high-tech therapies. Previously, ESTEVE enhanced its focus on rare diseases with acquisitions and licensing agreements for specialized treatments. The transaction is contingent upon standard regulatory approvals.
Sectors
- Pharmaceuticals
- Healthcare
Geography
- Spain – ESTEVE is headquartered in Barcelona, Spain, and the company is involved in this strategic acquisition.
- Global – The acquisition covers more than 50 countries, indicating a broad global impact of the deal.
Industry
- Pharmaceuticals – The industry involved is pharmaceuticals, as the article discusses the acquisition of a drug used in cancer treatment.
- Healthcare – The healthcare industry is relevant as the acquisition pertains to treatments for medullary thyroid cancer and other specialized medical needs.
Financials
- Not disclosed – The financial terms of the acquisition deal between ESTEVE and Sanofi were not disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ESTEVE | Bidding Company | Company | A global pharmaceutical company based in Barcelona, focused on specialized treatments. |
| Sanofi | Selling Company | Company | A multinational pharmaceutical company selling rights to the drug Caprelsa®. |
| José María Giménez-Arnau | Chief Scientific & Medical Officer | Person | A key executive at ESTEVE involved in advancing cancer treatment strategies. |
| Jacob Tolstrup | Chief Commercial Officer | Person | Executive at ESTEVE emphasizing the expansion of the company's high-tech therapy portfolio. |